France· FR:66818044
VALGANCICLOVIR CRISTERS 450 mg, comprimé pelliculé
A valganciclovir product containing chlorhydrate de valganciclovir, registered in France by CRISTERS, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Valganciclovir is registered in 18 of 19 countries.
Countries holding a registration under ATC J05AB14 (valganciclovir), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 11 of them publish a price we can compare per daily dose
Valganciclovir · ATC J05AB14
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of valganciclovir costs, country by country.
Normalised to the WHO defined daily dose (0.9 g), the median price runs from $3.83 in United States to $35.27 in Italy — a ×9.2 gap.
- France: $22.39 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Valganciclovir · price per daily dose (0.9 g)
USD · FX 28 Sept 2026
- IT Italy$35.27
- CH Switzerland$35.18
- FR France$22.39
- US United States$3.83 (acquisition cost)
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE DE VALGANCICLOVIR
- Manufacturer
- CRISTERS
- Country
- France (FR)
- ATC code
- J05AB14
- ATC class
- Valganciclovir
- Defined daily dose
- 0.9 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930043257flacon(s) polyéthylène haute densité (PEHD) de 60 comprimé(s) avec fermeture de sécurité enfantEUR 590.11
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
283 interactions on record for valganciclovir.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Valganciclovir · interactions on record
283 records
- 8 severe
- 193 moderate
- 82 info
Most severe, free to view
- CladribineL01BB04severe
- TrospiumA03AB20moderate
- Amphotericin BA07AA07moderate
- TrospiumG04BD09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Valganciclovir in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCYTEVIX+pharma arzneimittel gmbh, Graz
- United StatesValcyteH2-Pharma, LLC
- SpainVALCYTE 450 mg COMPRIMIDOS RECUBIERTOS CON PELICULA.Cheplapharm Arzneimittel Gmbh
- NetherlandsAlvanocyt 450 mg, filmomhulde tablettenZentiva k.s.
- FinlandValcyteParanova Oy
- SwedenValganciclovir Accord 450 mg Filmdragerad tablettAccord Healthcare B.V.
- ItalyVALCYTECHEPLAPHARM ARZNEIMITTEL GMBH
- NorwayValcyteCheplapharm Arzneimittel GmbH
Authorised across Europe · EMA
The same active substance is authorised in 28 EEA countries. Names it is sold under:
- Austria · Valcyte, Valganciclovir +pharma
- Belgium · Valcyte, Valganciclovir Sandoz
- Bulgaria · Алваноцит, Валцит
- Cyprus · Valcyte, Valganciclovir Accord
- Czechia · Cytevix, Valcyte
- Germany · Valcyte, Valganaxiro
- Denmark · Valcyte, Valganciclovir "medical Valley"
- Estonia · Valganciclovir Accord, Valganciclovir Sandoz
- Spain · Valcyte, Valganciclovir Accord
- Finland · Valcyte, Valganciclovir Accord
- United Kingdom (Northern Ireland) · Valcyte, Valganciclovir Accord Healthcare
- Greece · Vagotrosin, Valcyte
- Croatia · Alvanocyt, Valcyte
- Hungary · Valcyte, Valdamin
- Ireland · Valcyte, Valganciclovir Accord Healthcare
- Iceland · Valcyte, Valganciclovir Medical Valley
- Italy · Valcyte, Valganciclovir Accord
- Lithuania · Valganciclovir Accord, Valganciclovir Sandoz
- Luxembourg · Valcyte
- Latvia · Valcyte, Valganciclovir Accord
- Netherlands · Alvanocyt, Valcyte
- Norway · Valcyte, Valganciclovir Accord
- Poland · Ceglar, Valcyte
- Portugal · Rovalcyte, Valganciclovir Accord
- Romania · Valganciclovir Zentiva
- Sweden · Valcyte, Valganciclovir Accord
- Slovenia · Ganaxa, Valcyte
- Slovakia · Valdamin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e5bb183b-98bc-42bc-a3af-ea82e2e9c7ab GET /v1/drugs/e5bb183b-98bc-42bc-a3af-ea82e2e9c7ab?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66818044",
"date_amm": "2016-06-20",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "CHLORHYDRATE DE VALGANCICLOVIR",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about valganciclovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.